Clinical Research Directory
Browse clinical research sites, groups, and studies.
Using Mirabegron to Control Arrhythmia-1
Sponsor: Cedars-Sinai Medical Center
Summary
To evaluate mirabegron's effect on ventricular arrhythmia control. The study will be conducted in ambulatory patients with ventricular tachycardia (VT), organic heart diseases, and an implantable cardioverter-defibrillator (ICD). The investigators will perform a pilot study involving 20 patients. Each will receive 50 mg of mirabegron. All will have neuECG recordings made before and 2 months after mirabegron. The data will be analyzed to test the proposed hypothesis.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
20
Start Date
2026-05
Completion Date
2028-05
Last Updated
2026-05-06
Healthy Volunteers
No
Interventions
Mirabegron
Mirabegron is a beta-3 agonist approved by FDA to treat overactive bladder. Our preclinical studies showed that it is antiarrhythmic in the ventricles.